Latest news

Orchard Therapeutics Appoints Frank Thomas as Chief Financial Officer and Chief Business Officer

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing.

Orchard Therapeutics announces today a strategic alliance with Généthon, to develop gene therapy for X-linked chronic granulomatous disease (“X-CGD”).